vs
Side-by-side financial comparison of SHORE BANCSHARES INC (SHBI) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $59.1M, roughly 1.6× SHORE BANCSHARES INC). On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs 11.8%). SHORE BANCSHARES INC produced more free cash flow last quarter ($59.2M vs $12.8M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 11.3%).
Shore Bancshares Inc. is a U.S. regional bank holding company headquartered in Maryland. It offers a full range of retail and commercial banking services, including deposit products, personal and commercial loans, and wealth management solutions, primarily serving local individual customers, small businesses and mid-sized enterprises in its operating regions.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
SHBI vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $59.1M | $92.9M |
| Net Profit | — | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | 35.2% | 24.1% |
| Net Margin | — | 25.0% |
| Revenue YoY | 11.8% | 23.3% |
| Net Profit YoY | — | 17.3% |
| EPS (diluted) | $0.48 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $59.1M | $92.9M | ||
| Q3 25 | $56.4M | $67.5M | ||
| Q2 25 | $56.6M | $63.2M | ||
| Q1 25 | $53.0M | $52.6M | ||
| Q4 24 | $52.9M | $75.4M | ||
| Q3 24 | $50.5M | $57.9M | ||
| Q2 24 | $50.6M | $52.7M | ||
| Q1 24 | $47.7M | $51.3M |
| Q4 25 | — | $23.2M | ||
| Q3 25 | $14.3M | $5.1M | ||
| Q2 25 | $15.5M | $-553.0K | ||
| Q1 25 | $13.8M | $-11.2M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | $11.2M | $-901.0K | ||
| Q2 24 | $11.2M | $-4.7M | ||
| Q1 24 | $8.2M | $-3.9M |
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 68.9% |
| Q4 25 | 35.2% | 24.1% | ||
| Q3 25 | 33.7% | 5.1% | ||
| Q2 25 | 36.5% | -3.2% | ||
| Q1 25 | 34.4% | -24.3% | ||
| Q4 24 | 34.3% | 24.5% | ||
| Q3 24 | 29.6% | -4.3% | ||
| Q2 24 | 29.7% | -11.5% | ||
| Q1 24 | 22.2% | -10.7% |
| Q4 25 | — | 25.0% | ||
| Q3 25 | 25.5% | 7.5% | ||
| Q2 25 | 27.4% | -0.9% | ||
| Q1 25 | 26.0% | -21.4% | ||
| Q4 24 | — | 26.3% | ||
| Q3 24 | 22.1% | -1.6% | ||
| Q2 24 | 22.2% | -8.9% | ||
| Q1 24 | 17.2% | -7.5% |
| Q4 25 | $0.48 | $0.46 | ||
| Q3 25 | $0.43 | $0.10 | ||
| Q2 25 | $0.46 | $-0.01 | ||
| Q1 25 | $0.41 | $-0.23 | ||
| Q4 24 | $0.39 | $0.40 | ||
| Q3 24 | $0.34 | $-0.02 | ||
| Q2 24 | $0.34 | $-0.10 | ||
| Q1 24 | $0.25 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $355.6M | $137.5M |
| Total DebtLower is stronger | $89.1M | — |
| Stockholders' EquityBook value | $589.9M | $354.6M |
| Total Assets | $6.3B | $488.0M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $355.6M | $137.5M | ||
| Q3 25 | $416.5M | $135.4M | ||
| Q2 25 | $185.0M | $116.9M | ||
| Q1 25 | $389.0M | $112.9M | ||
| Q4 24 | $459.9M | $116.2M | ||
| Q3 24 | $183.6M | $101.7M | ||
| Q2 24 | $138.9M | $102.5M | ||
| Q1 24 | $114.6M | $110.6M |
| Q4 25 | $89.1M | — | ||
| Q3 25 | $74.5M | — | ||
| Q2 25 | $74.2M | — | ||
| Q1 25 | $74.0M | — | ||
| Q4 24 | $73.7M | — | ||
| Q3 24 | $123.5M | — | ||
| Q2 24 | $122.8M | — | ||
| Q1 24 | $72.6M | — |
| Q4 25 | $589.9M | $354.6M | ||
| Q3 25 | $577.2M | $321.9M | ||
| Q2 25 | $565.2M | $306.8M | ||
| Q1 25 | $552.5M | $295.5M | ||
| Q4 24 | $541.1M | $292.0M | ||
| Q3 24 | $533.3M | $257.5M | ||
| Q2 24 | $522.8M | $243.0M | ||
| Q1 24 | $515.2M | $233.9M |
| Q4 25 | $6.3B | $488.0M | ||
| Q3 25 | $6.3B | $453.3M | ||
| Q2 25 | $6.0B | $435.6M | ||
| Q1 25 | $6.2B | $424.6M | ||
| Q4 24 | $6.2B | $432.7M | ||
| Q3 24 | $5.9B | $390.4M | ||
| Q2 24 | $5.9B | $376.8M | ||
| Q1 24 | $5.8B | $356.7M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.13× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.13× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.23× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $62.4M | $15.0M |
| Free Cash FlowOCF − Capex | $59.2M | $12.8M |
| FCF MarginFCF / Revenue | 100.2% | 13.8% |
| Capex IntensityCapex / Revenue | 5.4% | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $110.6M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $62.4M | $15.0M | ||
| Q3 25 | $42.5M | $22.1M | ||
| Q2 25 | $-8.3M | $8.2M | ||
| Q1 25 | $19.8M | $6.6M | ||
| Q4 24 | $46.9M | $22.2M | ||
| Q3 24 | $9.1M | $10.2M | ||
| Q2 24 | $3.0M | $18.5M | ||
| Q1 24 | $2.4M | $7.2M |
| Q4 25 | $59.2M | $12.8M | ||
| Q3 25 | $41.9M | $19.5M | ||
| Q2 25 | $-9.2M | $81.0K | ||
| Q1 25 | $18.8M | $-7.6M | ||
| Q4 24 | $41.7M | $8.5M | ||
| Q3 24 | $8.4M | $-9.2M | ||
| Q2 24 | $1.4M | $1.8M | ||
| Q1 24 | $614.0K | $-6.8M |
| Q4 25 | 100.2% | 13.8% | ||
| Q3 25 | 74.3% | 28.8% | ||
| Q2 25 | -16.3% | 0.1% | ||
| Q1 25 | 35.4% | -14.5% | ||
| Q4 24 | 78.8% | 11.2% | ||
| Q3 24 | 16.7% | -15.9% | ||
| Q2 24 | 2.9% | 3.4% | ||
| Q1 24 | 1.3% | -13.3% |
| Q4 25 | 5.4% | 2.4% | ||
| Q3 25 | 1.0% | 3.9% | ||
| Q2 25 | 1.6% | 12.9% | ||
| Q1 25 | 1.9% | 27.0% | ||
| Q4 24 | 9.9% | 18.3% | ||
| Q3 24 | 1.2% | 33.5% | ||
| Q2 24 | 3.1% | 31.8% | ||
| Q1 24 | 3.7% | 27.3% |
| Q4 25 | — | 0.65× | ||
| Q3 25 | 2.96× | 4.35× | ||
| Q2 25 | -0.54× | — | ||
| Q1 25 | 1.44× | — | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | 0.81× | — | ||
| Q2 24 | 0.27× | — | ||
| Q1 24 | 0.29× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SHBI
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
